title: Treatment of respiratory syncytial virus infection in haemopoietic stem cell transplant recipients with aerosolized ribavirin and the humanized monoclonal antibody palivizumab: a single centre experience.
authors.forename: Dimitris A
authors.initials: DA
authors.lastname: Tsitsikas
authors.forename: Heather
authors.initials: H
authors.lastname: Oakervee
authors.forename: Jamie D
authors.initials: JD
authors.lastname: Cavenagh
authors.forename: John
authors.initials: J
authors.lastname: Gribben
authors.forename: Samir G
authors.initials: SG
authors.lastname: Agrawal
authors.forename: Frank M
authors.initials: FM
authors.lastname: Mattes
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000627:therapeutic use*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D016867:Immunocompromised Host; D008297:Male; D008875:Middle Aged; D000069455:Palivizumab; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy*; D012254:Ribavirin / Q000627:therapeutic use*
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D012254:Ribavirin; D000069455:Palivizumab